Free Trial

Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results, Hits Expectations

Exagen logo with Medical background

Exagen (NASDAQ:XGN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20), RTT News reports. The business had revenue of $15.50 million during the quarter, compared to analysts' expectations of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same quarter in the previous year, the business posted ($0.19) EPS.

Exagen Trading Down 7.3 %

Shares of NASDAQ XGN traded down $0.45 during midday trading on Friday, reaching $5.71. 357,579 shares of the stock were exchanged, compared to its average volume of 108,589. The company has a market capitalization of $102.79 million, a price-to-earnings ratio of -6.07 and a beta of 1.50. Exagen has a 12 month low of $1.38 and a 12 month high of $7.20. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The business has a 50-day simple moving average of $4.54 and a two-hundred day simple moving average of $4.11.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on XGN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of Exagen in a research report on Monday, January 13th. BTIG Research reissued a "buy" rating on shares of Exagen in a report on Wednesday. Finally, William Blair reiterated an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th.

Get Our Latest Research Report on Exagen

About Exagen

(Get Free Report)

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

See Also

Earnings History for Exagen (NASDAQ:XGN)

Should You Invest $1,000 in Exagen Right Now?

Before you consider Exagen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exagen wasn't on the list.

While Exagen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines